Mendes S C, Tibbe J M, Veenhof M, Both S, Oner F C, van Blitterswijk C A, de Bruijn J D
IsoTis NV, Prof. Bronkhorstlaan 10, 3723 MB Bilthoven, The Netherlands.
J Mater Sci Mater Med. 2004 Oct;15(10):1123-8. doi: 10.1023/B:JMSM.0000046394.53153.21.
The use of cell therapies in bone reconstruction has been the subject of extensive research. It is known that human bone marrow stromal cell (HBMSC) cultures contain a population of progenitor cells capable of differentiation towards the osteogenic lineage. In the present study, the correlation between the in vitro osteogenic potential of HBMSC cultures and their capacity to form bone in vivo was investigated. HBMSC cultures were established from 14 different donors. Fourth passage cells were examined for the expression of alkaline phosphatase (ALP), procollagen I (PCI) and osteopontin (OP), through flow cytometry and the effect of the osteogenic differentiation factor dexamethasone (Dex) on this expression was evaluated. In addition, the capacity of the cultures to induce in vivo bone formation was analysed by culturing the cells on porous hydroxyapatite (HA) scaffolds followed by subcutaneous implantation of these constructs in nude mice. Results showed expression of PCI, OP and ALP in all cultures, irrespective of the presence of Dex in the culture medium. Dex failed to have a significant effect on the expression of PCI and OP but it induced a consistent increase in the relative amount of cells expressing ALP. Nevertheless, although in vitro testing clearly indicated osteogenic potential in all cultures, HBMSC from six of the 14 tested donors did not form bone in vivo. The results, therefore, demonstrate that neither the expression of PCI, OP and ALP nor the absolute increase in Dex-stimulated ALP expression can as yet be used as predictive markers for in vivo bone formation by HBMSC. However, preliminary data indicate that not the absolute, but the relative increase in the percentage of ALP expressing cells caused by Dex stimulation may be related to the ability of the HBMSC to form bone.
细胞疗法在骨重建中的应用一直是广泛研究的主题。众所周知,人骨髓基质细胞(HBMSC)培养物中含有一群能够向成骨谱系分化的祖细胞。在本研究中,研究了HBMSC培养物的体外成骨潜力与其在体内形成骨的能力之间的相关性。从14个不同供体建立了HBMSC培养物。通过流式细胞术检测第四代细胞中碱性磷酸酶(ALP)、I型前胶原(PCI)和骨桥蛋白(OP)的表达,并评估成骨分化因子地塞米松(Dex)对该表达的影响。此外,通过将细胞接种在多孔羟基磷灰石(HA)支架上,然后将这些构建体皮下植入裸鼠体内,分析培养物诱导体内骨形成的能力。结果显示,所有培养物中均有PCI、OP和ALP的表达,无论培养基中是否存在Dex。Dex对PCI和OP的表达没有显著影响,但它导致表达ALP的细胞相对数量持续增加。然而,尽管体外测试清楚地表明所有培养物都有成骨潜力,但14个测试供体中有6个的HBMSC在体内没有形成骨。因此,结果表明,PCI、OP和ALP的表达以及Dex刺激的ALP表达的绝对增加都还不能用作HBMSC体内骨形成的预测标志物。然而,初步数据表明,不是绝对的,而是Dex刺激引起的表达ALP的细胞百分比的相对增加可能与HBMSC形成骨的能力有关。